Fulcrum Therapeutics, Inc.
NASDAQ:FULCBiotechnology
+$0.06 today
- Market cap
- $284.14M
- Beta
- 2.92
- P/E (TTM)
- -3.6
- EPS (TTM)
- -$1.00
Volume 0.63M
Average 1.78M
FULC Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
Fulcrum Therapeutics, Inc.NASDAQ: FULC
Operating Expenses · Q1 FY2026 · quarter ended Mar 2026
Operating expenses growth accelerates
Q1 FY2026 operating expenses of $21.85M rose 212.2% year over year, ahead of the +84.2% change in trailing-twelve-month operating expenses. Sequentially, it fell 5.0% from the prior quarter. Over 3 fiscal years it compounded at +25.6% a year.
Context
- Operating expenses increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +212.2% holds above the trailing-twelve-month pace of +84.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 83.38M USD
- Year-over-year change
- +116.5%
- 4-year CAGR
- +28.6%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 83.38M | +116.5% |
| FY2024 | 2024-12-31 | 38.51M | -7.6% |
| FY2023 | 2023-12-31 | 41.67M | -1.1% |
| FY2022 | 2022-12-31 | 42.12M | +38.0% |
| FY2021 | 2021-12-31 | 30.52M | — |
Operating Expenses vs competitors
How FULC compares with its peers on the latest reported figures
- FULC's LTM Mar 2026 operating expenses of $86.21M is the 6th highest of the 10 companies compared; the peer median is $93.22M.
- Its year-over-year change of +84.2% is the 2nd highest of 10, against a peer median of +14.9%.
- Over three fiscal years its annual growth of +25.6% compares with a peer median of +19.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $234.87M | +104.1% | +34.7% | 369.9% | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $218.08M | -20.5% | +20.2% | — |
| LTM Mar 2026 | $190.31M | -2.8% | -18.0% | 240.4% | |
| LTM Mar 2026 | $104.02M | -36.9% | -9.1% | 1051.5% | |
| LTM Mar 2026 | $93.22M | -48.9% | +26.7% | 133.9% | |
| LTM Mar 2026 | $86.21M | +84.2% | +25.6% | — | |
| LTM Mar 2026 | $74.43M | +18.8% | +19.7% | — | |
| LTM Mar 2026 | $72.51M | +27.8% | +23.3% | — | |
| LTM Mar 2026 | $70.72M | +14.9% | -10.8% | 1583.9% | |
| LTM Mar 2026 | $52.19M | +70.5% | -0.9% | 353.1% | |
| Peer median (excluding FULC) | $93.22M | +14.9% | +19.7% | 361.5% | |
Competitors are the stored peer set for FULC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 19.16M | 6.34M | 2.81M | 80M | 0 |
| Cost of Revenue | 69.7M | 76.78M | 71.8M | 63.39M | 1.39M |
| Gross Profit | (50.54M) | (70.44M) | (69M) | 16.61M | (1.39M) |
| Gross Margin | -263.7% | -1110.7% | -2459.8% | 20.8% | — |
| Research & Development | 69.7M | 76.78M | 71.8M | 63.39M | 56.1M |
| Selling, General & Admin | 30.52M | 41.69M | 41.67M | 36.45M | 28.67M |
| Operating Expenses | 30.52M | 42.12M | 41.67M | 38.51M | 83.38M |
| Depreciation & Amortization | 2.52M | 2.41M | 2.17M | 1.59M | 1.39M |
| EBITDA | (78.33M) | (109.72M) | (95.16M) | (18.24M) | (73.49M) |
| EBITDA Margin | -408.8% | -1730.1% | -3392.6% | -22.8% | — |
| Operating Income | (81.05M) | (112.56M) | (110.66M) | (21.9M) | (84.77M) |
| Operating Margin | -423.0% | -1774.9% | -3945.2% | -27.4% | — |
| Interest Income | 207K | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 207K | 2.69M | 13.33M | 12.17M | 9.89M |
| Income Before Tax | (80.85M) | (109.87M) | (97.34M) | (9.73M) | (74.88M) |
| Pre-Tax Margin | -421.9% | -1732.4% | -3470.1% | -12.2% | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (80.85M) | (109.87M) | (97.34M) | (9.73M) | (74.88M) |
| Net Margin | -421.9% | -1732.4% | -3470.1% | -12.2% | — |
| EPS (Basic) | (2.22) | (2.35) | (1.59) | (0.16) | (1.18) |
| EPS (Diluted) | (2.22) | (2.35) | (1.59) | (0.16) | (1.18) |
| Weighted Avg Shares | 35.36M | 44.99M | 61.31M | 61.98M | 63.36M |
| Weighted Avg Shares (Diluted) | 35.36M | 44.99M | 61.31M | 61.98M | 63.36M |
Fulcrum Therapeutics, Inc.
NASDAQ:FULC
Intrinsic Alpha fair value
Locked
Current Price
$3.72
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.